NASDAQ · RKDA

Arcadia Biosciences, Inc.

Basic Materials · Agricultural Inputs

$0.48▲ 3.80% ($0.02)at close

After hours$0.48▼ 0.02%5:16 PM ET

52-week

$0.38$6.71

Market cap

$738.84K

P/E

-0.06

EPS (TTM)

-$8.14

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -8%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.48

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Year 1 growth 0% · Ending margin 0% · Discount rate 7.87%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 12:57 AM UTC · cache

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -86.4%Revenue (TTM): -12.24%FCF (TTM): 66.55%P/S: 0th pct

What changed

The stock fell 86.4% over the last year. Revenue declined 12.24% over the trailing twelve months. Operating margin moved from -208.01% to -85.52%. Free cash flow grew 66.55% over the trailing twelve months.

What the market seems to be pricing

The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -85.52%. A decisive move in revenue — currently down 12.24% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products.

CEOThomas J. Schaefer

SectorBasic Materials

IndustryAgricultural Inputs

Employees8

IPO dateMay 15, 2015

https://www.arcadiabio.com

Market multiples

Forward P/E—

EV/EBITDA-1.07

Enterprise value$2.45M

Stock splits

Mar 1, 2023↓ Reverse

Every 40 shares became 1

-97%

Jan 24, 2018↓ Reverse

Every 20 shares became 1

-95%

Profitability & growth

Revenue growth-0.82%

Gross margin (FY2025)36.23%▼5.0ppvs FY2024

Operating margin (FY2025)-205.74%▼133.4ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$6.00▲1156.54%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.46 · Revenue est $2.4M

View

NASDAQ · RKDA

Arcadia Biosciences, Inc.

Basic Materials · Agricultural Inputs

$0.48▲ 3.80% ($0.02)at close

After hours$0.48▼ 0.02%5:16 PM ET

52-week

$0.38$6.71

Market cap

$738.84K

P/E

-0.06

EPS (TTM)

-$8.14

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -8%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.48

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Year 1 growth 0% · Ending margin 0% · Discount rate 7.87%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 12:57 AM UTC · cache

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -86.4%Revenue (TTM): -12.24%FCF (TTM): 66.55%P/S: 0th pct

What changed

What the market seems to be pricing

What would invalidate this read

Operating margin currently stands at -85.52%. A decisive move in revenue — currently down 12.24% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products.

CEOThomas J. Schaefer

SectorBasic Materials

IndustryAgricultural Inputs

Employees8

IPO dateMay 15, 2015

https://www.arcadiabio.com

Market multiples

Forward P/E—

EV/EBITDA-1.07

Enterprise value$2.45M

Stock splits

Mar 1, 2023↓ Reverse

Every 40 shares became 1

-97%

Jan 24, 2018↓ Reverse

Every 20 shares became 1

-95%

Profitability & growth

Revenue growth-0.82%

Gross margin (FY2025)36.23%▼5.0ppvs FY2024

Operating margin (FY2025)-205.74%▼133.4ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$6.00▲1156.54%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.46 · Revenue est $2.4M

View